Study of the electrocardiograms prior to the activation of the infarction code.

Inclusion criteria

-Adults

-Chest pain or symptoms suggestive of myocardial ischemia

-EST at point J on the 12-lead electrocardiogram prior to activation of the infarction code in two contiguous leads ≥ 0.1 mV and in V2 and V3 ≥0.2 mV

Exclusion criteria

-Complete branch block.

-Patients with a troponin curve of myocardial necrosis will be excluded, even if they do not present significant stenosis of the epicardial coronary artery.

-EST ≤ 0.1 mV with pathological Q wave suggestive of previous chronic infarction.

Cost analysis of elective rotational atherectomy in patients with coronary lesions with severe obstruction and calcification and chronic renal failure (CKD) versus the conventional rescue rotational atherectomy strategy

Inclusion criteria:

• Patients older than 18 years
• Patients with GFR less than 60 ml/min/1,73 m2.
• Severe coronary angiography calcification (both sides of the artery)
• Stenosis > or = 70% by visual estimation in a coronary artery greater than 2,5 mm.
• Any clinical scenario except AMI (in the first 7 days of evolution).

Exclusion criteria:

• AMI in the first 7 days of evolution.
• Injury to a single patent vessel.
• Patients with calcified lesions with an angulation >60º, dissections, lesions with thrombus and degenerated saphenous bridges.
• Patients with clinical or hemodynamic instability,
• Patients with allergies to iodinated contrast agents
• Patients with significant comorbidity and a life expectancy of less than 1 year

Implementation of a decision support system and its effect on the optimization of lipid-lowering therapies in patients with acute coronary syndrome.

Inclusion criteria

• Age ≥18 to <80 years
• Provide written informed consent
• Present to a study center with ACS without prior treatment with LLT, in monotherapy
  or in combination.
• Willing to take lipid-lowering treatments for secondary prevention of
  cardiovascular diseases.

Exclusion criteria

• You cannot or do not want to use lipid-lowering treatments other than statins for the care of ACS.
• Written informed consent cannot be provided
• Measurement of LDL-C < 1,8 mmol/L on admission.

It wants to demonstrate the efficacy and safety of Milvexian, an oral factor XIa inhibitor, after a recent acute coronary syndrome and to verify the reduction in the risk of major cardiovascular events.

Inclusion criteria

-Type of participant and characteristics of the disease

a) Clinical syndrome compatible with spontaneous cardiac ischemia

b) Diagnosis of acute coronary syndrome

c) Elevation of cardiac biomarkers.

-Participants must have at least 2 of the following risk factors:|

a) 65 years or older

b) Diabetes mellitus

c) History of a previous MI

d) multivessel CAD

e) History of CABG surgery before the index ACS event

f) History of PAD or cerebrovascular disease

g) Conservative management

-One or more of the following high-risk angiographic features

to. Total stent length > 30 mm

b. Thrombotic target lesion

C. Bifurcation lesion treated with more than one stent

d. Calcified target lesion treated with atherectomy

and. Treatment of obstructive left main artery or proximal left anterior descending artery for index ACS.

Exclusion Criteria

1. MI secondary to ischemia due to increased oxygen demand or decreased supply (type 2 MI) or periprocedural MI as an index event for ACS.

2. Minimal or no obstructive CAD on angiography performed for the index ACS event prior to any PCI (i.e., <50% visual stenosis as determined by the investigator).

3. Planned CABG or staged PCI after randomization

4. Any condition requiring chronic anticoagulation at the discretion of the investigator and/or local guidelines.

5. Conditions with a significantly increased risk of bleeding

6. Requires permanent dialysis or has an eGFR <15 ml/min/1,73 m2 at screening

7. Current active liver disease

8. History of ischemic stroke or TIA

9. Killip Class 3 or 4 at the time of randomization

10. History of any significant drug allergies.

11. Known aPTT prolongation > 1,5 times ULN or known congenital FXI deficiency

It studied the efficacy, defined as success of the procedure defined as performance of intracoronary lithotripsy without in-hospital complications with good angiographic result.

The results of this clinical trial have been published in the prestigious journal The New England Journal of Medicine

It studied patients over 65 years of age with cardiovascular risk factors and heart attack in the previous six months, who were randomized to standard medical treatment with aspirin, ACEIs and statins vs. Polypill (medication that included the previous ones in a single tablet). assessed therapeutic compliance and the occurrence of cardiovascular events in each group.